Monoclonal antibodies targeting the calcitonin gene-related peptide pathway represent a new class of mechanism-specific, migraine-targeted therapies available for migraine prevention. To date, four monoclonal antibodies have demonstrated efficacy in phase II and III trials, significantly reducing migraine days per month versus placebo with rapid onset of action. While their efficacy may be considered similar to existing preventive options, their true value may lie in an improved tolerability profile, with high specificity and selectivity for the calcitonin gene-related peptide receptor or ligand reducing the potential for off-target binding and toxicity. The infrequent parenteral administration of these therapeutic proteins, and lack of requirement for dose titration, has potential to simplify treatment selection and use for clinicians and patients. However, the treatments have not yet been tested in real-world settings in patients with the range of comorbid conditions encountered in routine clinical practice, and longer-term data on safety, efficacy, and treatment persistence are required. If data from real-world settings can confirm the initial clinical trial findings, it is hoped that antibodies antagonizing the calcitonin gene-related peptide pathway will be able to improve quality of life for patients with episodic and chronic migraine, and help relieve the huge patient and societal burden of migraine. Novel treatments designed to target the specific pathophysiology of migraine could have an important place in future migraine management.
or migraine days of at least 50% within 3 months, and reduced migraine intensity and duration. 2, 5 Reduction in use of acute migraine treatmentmeasured through a reduction in the number of migraine-specific medication days and pain medication days -is also important to reduce the risks of adverse events (AEs), medication-overuse headache, and chronification of migraine. 6, 7 Improved responsiveness to acute treatment of attacks is a further goal of preventive therapy. 3 However, although around 40% of people with migraine would benefit from preventive treatment, only a minority of these patients receive it. 8 Treatment failure resulting from AEs and lack of efficacy is common among those receiving preventive therapy, 9 and some patients do not want to take medication on a daily basis. There has been a great need for new preventive treatment options 1 that are acceptable to, and can achieve the management goals of, both patients and clinicians. 10, 11 LIMITATIONS OF THE CURRENT STANDARD OF CARE IN MIGRAINE PREVENTION Numerous medications are currently used to prevent chronic and episodic migraine, including betablockers, calcium channel blockers, antiepileptic drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), However, none were specifically developed for the treatment of migraine, and their mechanism of action in preventing migraine is unclear. The use of oral preventive therapy is limited in some cases by tachyphylaxis, and more commonly by poor tolerability, with common side effects including weight gain, fatigue, depression, mood changes, cognitive slowing, and gastrointestinal symptoms (Table 1) . 10, 16 Among the predominantly young and female migraine population, weight gain and sedation are of particular concern. 17 Contraindications, drug interactions, and potential for exacerbation of co-existing conditions are further limitations; comorbidities are common in patients with migraine, and must be considered carefully when selecting a preventive treatment.
12
Rates of adherence and persistence to oral prophylactic medications are low, in clinical trials and clinical practice (Table 2) . [18] [19] [20] [21] [22] [23] [24] Regardless of the medication class, treatment discontinuation, switching, or delay in taking medication occur frequently.
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Addition of a second (or third) preventive medication is also common practice in some parts of the world such as the USA -not in Europe -although evidence from prospective controlled trials in support of combination therapy is lacking. 26 A retrospective US claims analysis found that only a quarter of patients with chronic migraine remained on their medication at 6 months, falling to around 14% at 1 year; 25 in a crosssectional survey, present or past users of preventive treatment had tried an average of 3-4 medications. 9 Across the classes of preventive medication, the most common reasons for discontinuation are poor tolerability and lack of efficacy. 9, 27, 28 The onset of action tends to be slow, with the effectiveness of oral preventive treatments usually assessed after a minimum of 2 months. 8 
ROLE OF NOVEL, TARGETED TREATMENTS IN MEETING GOALS OF PREVENTIVE THERAPY
The neuropeptide calcitonin gene-related peptide (CGRP) pathway has been shown to have a pivotal role in migraine pathophysiology, 29 and small molecule inhibitors have demonstrated proof of principle for CGRP pathway antagonism in acute migraine therapy. 30 Four monoclonal antibodies (mAbs) that antagonize the CGRP pathway are in late-stage development for migraine prevention: galcanezumab, 31 eptinezumab, 32 and fremanezumab 20, 33 (which all target the CGRP peptide), and erenumab (the only fully human mAb of the four, and the only one designed to target the CGRP receptor). 18, 21 All four mAbs have demonstrated efficacy versus placebo in preventing episodic and chronic migraine in phase II or III randomized trials of up to 6 months' duration 18, 20, 21, [31] [32] [33] [34] Across the four therapies, a relative reduction (beyond that observed for placebo) in monthly migraine days of up to 2.6 days was observed in patients with episodic migraine. 18, 33, [35] [36] [37] and of up to 2.5 days in patients with chronic migraine. 20, 21, 38, 39 In the published phase III trials, erenumab in episodic migraine showed a relative (vs placebo) reduction from baseline in monthly migraine days of 1.4 days (for the 70 mg monthly dose) and 1.9 days (140 mg monthly; absolute reduction 23.7 days); P < .001 each dose) in treatment weeks 12-24; 18 with fremanezumab in chronic migraine, the relative reduction in average number of headache days/month was 1.8 days with a quarterly dose and 2.1 days with a monthly dose (P < .001; absolute reduction 24.6 days) in weeks 1-12. 20 Perhaps more clinically meaningful is the responder rate (proportion of patients achieving a given reduction in migraine days or mean monthly migraine days). In the 3-month, phase III fremanezumab trial (in chronic migraine), up to 41% of patients receiving fremanezumab, compared with 18% of patients in the placebo arm, had 50% reduction in mean monthly headache days (P < .001). Among patients with episodic migraine in the phase III erenumab trial, up to 50% of those receiving erenumab over 6 months, compared with 27% receiving placebo, had 50% reduction in mean monthly migraine days (P < .001). 18 Notably, some patients treated with mAb therapies achieved a complete response. In phase III studies in episodic migraine, up to 16% of those receiving galcanezumab (vs 6% for placebo) over the 6-month treatment period had a 100% reduction in migraine days (P < .001), and an average of 20% of patients receiving eptinezumab had no migraines in a given month (from month 1 to month 6). 40, 41 In chronic migraine, up to 4.3% of patients treated with erenumab achieved a 100% reduction in monthly migraine days from baseline to the last month of a 3-month double-blind treatment period, versus 0.4% with placebo (P 5 .002). While reports of these phase III data on responder rates for mAb therapies have generated interest, it must be pointed out that they are lower than what was expected from the Phase II trials with these agents. Longer term clinical data on mAb therapies would be valuable to understand responder rates and profiles.
One-year interim data from a 5-year open-label extension (OLE) of a phase II study of erenumab 70 mg in episodic migraine (median exposure 575 days) suggest that the benefits of mAb therapy may be durable (Fig. 1) . 42 Efficacy with erenumab was sustained to 15 months, with a mean reduction of 5 migraine days/month compared with the parent study baseline. At month 15, 65% and 42% of patients achieved a reduction in monthly migraine days of 50% and 75%, respectively, and a quarter of patients showed a 100% reduction. 42 In an open-label study with galcanezumab, the overall least squares mean change in monthly migraine days was up to 6.5 days over 12 months. 43 Threeyear data from the erenumab extension study are awaited, although the limitations of OLE data (including use of "as observed" analyses that omit patients who discontinued, and lack of a control group) must be kept in mind. Efficacy data from ongoing long-term studies with eptinezumab, 44 fremanezumab, 45 and galcanezumab, 46 are also awaited. The information to date suggests that the mAb therapies reduced days of use of acute migraine therapy compared with placebo. 18, 20, 38, 39 Data from the OLE study with erenumab in episodic migraine appear to indicate that this effect is sustained over time, with a mean reduction from baseline of 2.4 monthly migraine-specific medication days through month 15 ( Fig. 1) . 42 In the phase II study in chronic migraine, erenumab also demonstrated efficacy in patients with medication overuse. 47 Patients with prior failure of preventive treatment were also shown to benefit from erenumab in prespecified subgroup analyses of studies in episodic and chronic migraine; 48,49 these patients have great unmet need, and are frequently encountered in clinical practice, particularly at specialist headache centers. Among patients on stable doses of other preventive migraine medications, fremanezumab showed efficacy in post hoc analyses as an add-on treatment; 50 however, placebo-controlled randomized prospective trials are needed to evaluate the use of the mAbs as add-on therapy. While a cautious approach is required in interpreting data from OLEs, due to the methodology involved, a described benefit of such studies is that they can provide additional safety information. 51 To date, the OLEs reported do seem to show that over a 2 to 3-year period there is no pathological safety signal associated with a CGRP receptor antibody in current clinical development for migraine. Consequently, there is hope that the mAb antagonists of the CGRP pathway may display advantages with respect to their tolerability profile. In contrast to other preventive agents and small molecule CGRP inhibitors, the mAbs are highly specific and selective for their molecular targets, with reduced potential for off-target binding and toxicity. As they are not eliminated via hepatic metabolism, the potential for drug-drug interactions is also reduced. 52, 53 There is no evidence yet that the mAbs can readily cross the blood-brain barrier, 54 potentially reducing the risk of central nervous system toxicity. In this selected clinical trial population of (otherwise healthy) people with migraine, safety and tolerability of the four mAbs appeared favorable; 34 AE profiles were broadly similar to those observed with placebo, and rates of AE-related discontinuation were low. 18, 20, 21, [31] [32] [33] [34] However, their safety in "real-world" clinical practice, among patients with commonly encountered comorbid conditions (eg, gastrointestinal disorders, auto-immune diseases), is currently untested. There are no data on the use of the mAb therapies during pregnancy and lactation; this is particularly important for very long-acting mAbs (long half-life time), where the drug will remain in the maternal circulation for an extended period of time.
In the OLE study of erenumab 70 mg, involving patients with episodic migraine who had completed a phase II parent study, the safety profile to 1 year (based on 555.4 patient-years' exposure) was similar to that of erenumab 70 mg in the doubleblind phase (23.9 patient years' exposure), and the incidence rate of common AEs (nasopharyngitis, upper respiratory tract infection, back pain, and influenza) was the same or lower than with placebo in the randomized trial. 42 No new safety concerns were identified during the extension phase, and there were no clinically significant changes in vital signs or laboratory findings. In an open-label safety study with galcanezumab 120 mg and 240 mg monthly in patients with episodic or chronic migraine, treatment was reported to be safe over 1 year, with no meaningful differences in safety and tolerability profiles between the two doses. AEs reported in 10% of patients included nasopharyngitis, upper respiratory tract infection, back pain, and sinusitis. 43 Injection-site reaction-related AEs over the 12-week double-blind placebo-controlled treatment period were reported in up to 5.6% of patients receiving erenumab (vs 3.2% with placebo) across four controlled trials, 55 and in 10% of patients in the long-term galcanezumab safety study. 43 Injection-site reactions were more frequent in the phase III trial of fremanezumab in chronic migraine (affecting 47% of fremanezumab and 40% of placebo patients), in which injection sites were systematically assessed for 60 minutes postdosing. 20 Antidrug antibodies have been detected with all four mAbs; neutralizing antibodies against erenumab were detected in 0-3% of patients in doubleblind studies, and 2.4% of patients in an OLE study at 15 months, with no observed effect of antibodies on efficacy or safety. 18, 21, 42, 56 CGRP is a potent vasodilator in critical conditions (such as cardiac angina), and may have a protective role in ischemic situations. 57 To date, no cardiovascular safety signals have emerged from clinical trials of the mAbs targeting the CGRP pathway. In addition, a dedicated clinical study of erenumab in patients with stable angina with documented coronary artery disease found no impact on exercise time (a surrogate of underlying myocardial ischemia), 58 suggesting that redundant mechanisms may promote compensatory vasodilation. In phase I and II studies, erenumab and galcanezumab were found to have no effect on blood pressure. 59, 60 Ease of use could represent a further potential advantage of the mAb antagonists of the CGRP pathway. The long half-life enables monthly parenteral administration (or quarterly dosing in the case of fremanezumab), contrasting with existing preventive medications that are typically taken orally one to three times per day. Avoidance of the daily pill burden may be a benefit for many patients, particularly younger patients who dislike the daily reminder of their condition. 53, 61 Of the four mAbs, eptinezumab is the only one to be administered intravenously rather than by subcutaneous injection, although a subcutaneous formulation is planned. 62 A prefilled injection pen has been developed for erenumab. Of note, the orally administered CGRP receptor blocker atogepant is also in development for migraine prevention. 63 Speed of onset appears rapid compared with currently available preventive treatments. With eptinezumab, preventive benefits were observed within the first 24 hours following intravenous infusion. 64, 65 With subcutaneously administered erenumab and fremanezumab, onset of efficacy was observed within one week.
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SHAPING THE FUTURE FOR PATIENTS AND CLINICIANS
Patients with chronic and frequent episodic migraine desire new medications that will reduce their migraine frequency, and thereby improve their ability to function normally. 68 In clinical trials, the mAb antagonists of the CGRP pathway showed improvements in patient-reported outcome (PRO) measures of disability, functioning, and quality of life (QoL). 36, 37, 67 In chronic migraine, improvements and fremanezumab. 20, 71, 72 Studies in episodic migraine have shown improvements in disability, functioning and/or QoL measures for erenumab, 37, [73] [74] [75] galcanezumab, 36 and fremanezumab, 33 and additionally for erenumab in the migraine physical function impact diary (MPFID) measure, 18, 76 which provides a more comprehensive evaluation of the impact of migraine on physical functioning. In episodic migraine, the everyday-activities score of the MPFID, transformed onto a 100-point scale, improved from baseline by 5.5 in the erenumab 70 mg group, 5.9 in the 140 mg group, and 3.3 in the placebo group; the physical impairment score of the MPFID improved by 4.2, 4.8, and 2.4 in the respective groups (all P < .001 vs placebo). 18 PRO improvements observed with the mAb therapies, for example in the MSQ domains, may be greater than those previously reported for topiramate, 77, 78 which has similar efficacy to the CGRP pathway antagonists in terms of reduction in migraine days. 22 One-year interim data from the erenumab OLE in episodic migraine showed that improvements in HIT-6 total score were maintained through month 15 (Fig. 2) , with around two-thirds of patients achieving at least a 5-point reduction. 42 MIDAS total score (Fig. 2) and subscores of presenteeism and absenteeism also showed sustained improvement from baseline, as did the MSQ dimensions of role and emotional function.
Although treatment persistence in real-world settings is unknown, high rates of continuation have been reported in the clinical trials. In chronic migraine, in the fremanezumab phase III trial up to 93% of patients in the two active drug arms, and 91% in the placebo arm, completed the 3-month study, with 2% of patients in each arm discontinuing because of AEs. 20 In episodic migraine, in a phase III study, 90% of patients receiving erenumab (87% in the placebo arm) completed the 6-month double-blind treatment phase, with 2.2% (2.5% with placebo) discontinuing because of AEs; 18 in the phase II OLE, 80% of patients completed 1 year of erenumab 70 mg treatment, with an exposure-adjusted rate of discontinuations due to AEs of 2.5 per 100 patient-years. 42 The 1-year galcanezumab open-label study was completed by 78% of patients, with 4.8% discontinuing because of AEs. 43 In comparison, 17% of patients receiving topiramate (200 mg/day) discontinued during the 3-month maintenance phase of a randomized controlled trial. 79 Corresponding mAb data relating to real-world clinical practice will be needed to determine whether these agents show advantages in terms of persistence over currently used options. 80 For clinicians, migraine-specific preventive therapies that show advantages in real-world practice would bring positive changes. Currently, discussion of the strengths and limitations of the numerous preventive options takes up considerable clinic time. The availability of this new therapeutic class might ease communication with patients, be timesaving for the physician, and potentially reduce the trial and error involved in finding an effective treatment strategy. 5 The migraine-specific therapies also potentially represent simpler handling for the clinician as the mAbs can be initiated at a therapeutic dose and the response can be assessed early. In contrast, in subgroups of patients with risk factors (eg, obesity), prescription will require more extensive information for the patient due to potential vascular interaction of anti-CGRP drugs. This also applies to subjects with coexisting autoimmune disorders; gastric ulcers and other conditions. Provider input and time will be needed, however, to support the parenteral administration of the mAb treatments; this will include patient training for self-injection of the subcutaneously administered mAbs, and infusion space and resource for intravenous eptinezumab. With all four mAbs, a challenge in the early days of use will be knowing if, when, and how to stop or switch therapy; no studies have yet assessed the effect on migraine of discontinuing or switching treatment. A limiting factor of the routine use of CGRPpathway-targeted mAbs in the clinic is their high cost. 80, 81 Due to these pricing considerations, these agents will -at least in Europe -not be first-line choices for patients with migraine. From a medical point of view, it is likely that they will tend to be used in patients who have failed or have not been able to tolerate other therapies.
ASPECTS FOR FURTHER STUDY
Evidence of longer-term efficacy, safety, and persistence on the mAb therapies is needed, and further results from long-term studies with all four mAb antagonists of the CGRP pathway are awaited. In addition, data from patient populations in routine clinical practice settings are required. It will be important to observe whether any differences emerge over time in the AE profile of the CGRP-receptor and -ligand antagonists, and whether the benefits of therapy are sustained after stopping treatment.
An appreciable proportion of patients in the clinical studies achieved 75% reduction in migraine days during their treatment with the CGRP-pathwaytargeted mAbs. If reliable clinical or biologic markers of "super-responders" were identified, then perhaps the concept of personalized migraine prevention based on mechanism could be explored.
CONCLUSION
If approved, mAbs antagonizing the CGRP pathway will be the first class of mechanismspecific, migraine-targeted treatments for migraine prevention.
Ongoing clinical studies, postmarketing surveillance, and clinical practice data will be needed for evidence of the long-term efficacy and safety of the new migraine preventive therapies, and of their effectiveness in different patient groups. Further understanding of migraine pathophysiology and the precise site of action of the mAbs is also needed. 54 However, the current clinical trial data suggest that migraine-specific antagonists of the CGRP pathway may have potential to enhance the QoL of patients with chronic and episodic migraine, and relieve the burden of this common and disabling condition.
